Evidence map›Paper›PMID 39359864›Full record

ArticleJournal of pharmaceutical policy and practice2024

Polypharmacy and potentially inappropriate medicine use in older adults with cancer: a multicenter cross-sectional study in Northwest Ethiopia oncologic centers.

Samuel Agegnew Wondm, Tilaye Arega Moges, Samuel Berihun Dagnew, Fisseha Nigussie Dagnew, Tirsit Ketsela Zeleke, Rahel Belete Abebe, Endalamaw Aschale Mihrete, Fasil Bayafers Tamene

Abstract read
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Samuel Agegnew WondmDepartment of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.ORCID https://orcid.org/0000-0002-0723-6804
Tilaye Arega MogesDepartment of Pharmacy, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.ORCID https://orcid.org/0000-0001-6813-8792
Samuel Berihun DagnewDepartment of Pharmacy, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.ORCID https://orcid.org/0000-0002-8938-4551
Fisseha Nigussie DagnewDepartment of Pharmacy, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Tirsit Ketsela ZelekeDepartment of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.ORCID https://orcid.org/0000-0003-3528-0703
Rahel Belete AbebeDepartment of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.ORCID https://orcid.org/0000-0002-2560-2951
Endalamaw Aschale MihreteDepartment of Pharmacy, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.
Fasil Bayafers TameneDepartment of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.ORCID https://orcid.org/0009-0005-3026-6584

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Most patients with cancer have comorbid conditions that necessitate advanced medical treatment. Polypharmacy (PP) and potentially inappropriate medicine (PIM) use is common among older adult patients with cancer. Not much research has been conducted on PP and PIM use among older adult patients with cancer in Ethiopian oncology centers. Therefore, this study aimed to evaluate the prevalence and determinants of PP and PIM use among older adults with cancer in Northwest Ethiopia oncology centers using the American Geriatrics Society (AGS) 2019 updated Beers criteria. Methods: This multicenter cross-sectional study was conducted among older adult patients with cancer from July 15-December 30, 2023 in Northwest Ethiopian oncology centers. The use of at least one drug included in the 2019 Beers criteria revisions was classified as potentially inappropriate medication use. To identify the factors influencing PP and PIM use, logistic regression analysis was performed. Results: Of the 310 samples aproched, 305(98.4% response rate) participated in the study. The prevalence of PP and PIM use were 70.2% (95% CI 64.9-75.1) and 63.0% (95% CI 57.4-68.8) respectively. Being female AOR:3.6; 95% CI:1.7-7.8; p =  0. 001, advanced age [(70-74 years) AOR:3.9; 95% CI:1.2-6.7; p =  0.046 and ≥75 years AOR:3.8; 95% CI:1.7-8.4; p =  0.0028], abnormal body weight (underweight AOR:5.5; 95% CI:1.5-9.6; p =  0.019, overweight AOR:5.1; 95% CI:1.5-7.3; p = 0.01 and obese AOR:5.6; 95% CI:1.5-9.3; p = 0.021) and comorbidities AOR:3.5; 95% CI:1.7-8.3; p =  0.0032 were statistically significant factors for PP. Advanced age [(70-74 years) AOR:5.5; 95% CI:1.4-9.8; p =  0.015 and ≥75 years AOR:3.3; 95% CI:1.5-7.1; p = 0.002)] and polypharmacy; AOR:7; 95% CI:3.4-9.4; p = 0.001 were statistically significant factors for PIM use. Conclusion: Polypharmacy and potentially inappropriate medicine use were prevalent among older adult patients with cancer. Ensuring safe medicines prescription practices for older patients with cancer requires understanding the issue, stopping unwarranted treatment, and replacing it with less toxic, age-appropriate medicines.

Indexed as

2019 Beers criteriaCancerdeterminantsinappropriateness of medicine useolder adultspolypharmacy

Identifiers

PMID39359864
PMCPMC11445903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.